Literature DB >> 20415631

Bipolar depression: overview and commentary.

Ross J Baldessarini1, Eduard Vieta, Joseph R Calabrese, Mauricio Tohen, Charles L Bowden.   

Abstract

Depressive phases are the most prevalent component of bipolar disorders, even with modern treatment. Bipolar depressive morbidity is often misdiagnosed and is limited in response to available treatments. These conditions are especially debilitating and are associated with psychiatric comorbidity, substance abuse, functional disability, and increased mortality owing to early suicide and accidents, and later medical illnesses. There is growing awareness that bipolar depression is one of the greatest challenges in modern psychiatry. It is essential to differentiate various forms of depression, dysthymia, and dysphoric mixed states of bipolar disorders from the clinical features of more common, unipolar major depressive disorders. In bipolar depression, antidepressant responses often are unsatisfactory, and these agents probably are overused. Emerging treatments, including several anticonvulsant and modern antipsychotic drugs, as well as lithium-alone or in selected combinations-are partially effective for bipolar depression. Interest in recognizing bipolar depression and seeking more effective, specific, and safer treatments for it are growing.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20415631     DOI: 10.3109/10673221003747955

Source DB:  PubMed          Journal:  Harv Rev Psychiatry        ISSN: 1067-3229            Impact factor:   3.732


  43 in total

1.  Stuck in a rut: rethinking depression and its treatment.

Authors:  Paul E Holtzheimer; Helen S Mayberg
Journal:  Trends Neurosci       Date:  2010-11-08       Impact factor: 13.837

Review 2.  [Pharmaceutical treatment of bipolar depression. Evidence from clinical guidelines and treatment recommendations].

Authors:  S Köhler; M Bauer; T Bschor
Journal:  Nervenarzt       Date:  2014-09       Impact factor: 1.214

3.  Dissimilar morbidity following initial mania versus mixed-states in type-I bipolar disorder.

Authors:  Ross J Baldessarini; Paola Salvatore; Hari-Mandir Kaur Khalsa; Mauricio Tohen
Journal:  J Affect Disord       Date:  2010-04-27       Impact factor: 4.839

4.  Age at onset versus family history and clinical outcomes in 1,665 international bipolar-I disorder patients.

Authors:  Ross J Baldessarini; Leonardo Tondo; Gustavo H Vazquez; Juan Undurraga; Lorenza Bolzani; Aysegul Yildiz; Hari-Mandir K Khalsa; Massimo Lai; Beatrice Lepri; Maria Lolich; Pier Mario Maffei; Paola Salvatore; Gianni L Faedda; Eduard Vieta; Mauricio Tohen
Journal:  World Psychiatry       Date:  2012-02       Impact factor: 49.548

Review 5.  Speed of antidepressant response to electroconvulsive therapy in bipolar disorder vs. major depressive disorder.

Authors:  Smita Agarkar; Stephen W Hurt; Robert C Young
Journal:  Psychiatry Res       Date:  2018-03-01       Impact factor: 3.222

6.  Potentiation of Endocrine Adverse Effects of Lithium by Enalapril and Verapamil.

Authors:  R Krysiak; B Okopien
Journal:  West Indian Med J       Date:  2014-08-29       Impact factor: 0.171

7.  Factors associated with functional recovery in bipolar disorder patients.

Authors:  Aliza P Wingo; Ross J Baldessarini; Paul E Holtzheimer; Philip D Harvey
Journal:  Bipolar Disord       Date:  2010-05       Impact factor: 6.744

Review 8.  Options for pharmacological treatment of refractory bipolar depression.

Authors:  Leonardo Tondo; Gustavo H Vázquez; Ross J Baldessarini
Journal:  Curr Psychiatry Rep       Date:  2014-02       Impact factor: 5.285

9.  Cortical thickness differences between bipolar depression and major depressive disorder.

Authors:  Martin J Lan; Binod Thapa Chhetry; Maria A Oquendo; M Elizabeth Sublette; Gregory Sullivan; J John Mann; Ramin V Parsey
Journal:  Bipolar Disord       Date:  2014-01-16       Impact factor: 6.744

Review 10.  Suicidal Behavior in Mood Disorders: Response to Pharmacological Treatment.

Authors:  Leonardo Tondo; Ross J Baldessarini
Journal:  Curr Psychiatry Rep       Date:  2016-09       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.